Convert o1.exchange O to AbbVie (Ondo Tokenized) ABBVON
O to ABBVON: 1 o1.exchange converts to 0.001768 ABBVON
Earn up to $2,000 when you buy $50 in crypto
Earn free crypto after making your first purchase. Terms apply.
Sum of median estimated savings and rewards earned, per user in 2021 across multiple Coinbase programs (excluding sweepstakes). This amount includes fee waivers from Coinbase One (excluding the subscription cost), rewards from Coinbase Card, and staking rewards.
About O and ABBVON
o1.exchange is climbing, while AbbVie (Ondo Tokenized) is falling this week. The current O to ABBVON conversion rate is 0.001768. Inversely, this means that if you convert 1 ABBVON you will get 565.76 O. The conversion rate of O/ABBVON has decreased by 2.34% in the last hour (ABBVON/O increased by 2.39%). In the last 24 hours, O/ABBVON grew by 14.03%, while ABBVON/O shrunk by 12.31%.
The exchange rate of o1.exchange is decreasing. The current value of 1 O is 0.001768 ABBVON. In other words, to buy 5 o1.exchange, it would cost you 0.008838 ABBVON. Inversely, 1 ABBVON would allow you to trade for 565.76 O while 50 ABBVON would convert to 28,288.13 O, not including platform or gas fees.
In the last 7 days, the exchange rate has fallen by 99.61%. Meanwhile, in the last 24 hours, the rate has changed by 99.62%, and that the highest exchange rate of 1 O to ABBVON was 0.5833 ABBVON and the lowest 24 hour value was 1 O for 0.4391 ABBVON. Last month, 1 O was worth 0.4549 ABBVON. Today, it's down 99.61%. Looking back a year, o1.exchange has changed by 0.00 ABBVON. That means that in a single year, the value of o1.exchange has grown by 0%.
o1.exchange Market Stats
$O is the native token of the o1.exchange platform, which focuses on enabling efficient and secure digital asset exchange. The platform's documentation provides details on its operational framework and token utility.
AbbVie (Ondo Tokenized) Market Stats
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Conversion tables
O to ABBVON values from Today at 6:04 am
0.5 O = 0.0008838 ABBVON |
1 O = 0.001768 ABBVON |
5 O = 0.008838 ABBVON |
10 O = 0.01768 ABBVON |
50 O = 0.08838 ABBVON |
100 O = 0.1768 ABBVON |
500 O = 0.8838 ABBVON |
1,000 O = 1.77 ABBVON |
ABBVON to O values from Today at 6:42 pm
0.5 ABBVON = 282.88 O |
1 ABBVON = 565.76 O |
5 ABBVON = 2,828.81 O |
10 ABBVON = 5,657.63 O |
50 ABBVON = 28,288.13 O |
100 ABBVON = 56,576.27 O |
500 ABBVON = 282,881.34 O |
1,000 ABBVON = 565,762.67 O |
O to ABBVON over time
O | Today | 24H -26,176.56% | 1M -25,638.81% | 1Y 100.00% |
|---|---|---|---|---|
0.5 O | 0.0008838 ABBVON | 0.2322 ABBVON | 0.2275 ABBVON | 0.00 ABBVON |
1 O | 0.001768 ABBVON | 0.4644 ABBVON | 0.4549 ABBVON | 0.00 ABBVON |
5 O | 0.008838 ABBVON | 2.32 ABBVON | 2.27 ABBVON | 0.00 ABBVON |
10 O | 0.01768 ABBVON | 4.64 ABBVON | 4.55 ABBVON | 0.00 ABBVON |
50 O | 0.08838 ABBVON | 23.22 ABBVON | 22.75 ABBVON | 0.00 ABBVON |
100 O | 0.1768 ABBVON | 46.44 ABBVON | 45.49 ABBVON | 0.00 ABBVON |
500 O | 0.8838 ABBVON | 232.22 ABBVON | 227.47 ABBVON | 0.00 ABBVON |
1,000 O | 1.77 ABBVON | 464.45 ABBVON | 454.94 ABBVON | 0.00 ABBVON |
Frequently asked questions
Buy o1.exchange with Coinbase
Create a Coinbase account to buy and sell o1.exchange on the most secure crypto exchange.
Related conversions
Learn how to buy popular cryptocurrencies
Popular prediction markets
Discover other cryptocurrencies to currency conversions
Discover other cryptocurrency conversions
Start your crypto portfolio today
Sign up for a Coinbase account today and see what the world of decentralized finance can do for you.
This content is being provided to you for informational purposes only, does not constitute an offer, or solicitation of an offer nor a recommendation by Coinbase to buy, sell, or hold any security, financial product, or instrument referenced in the content, and does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Data presented may reflect asset prices traded on the Coinbase exchange as well as other cryptocurrency exchanges and market data platform. Coinbase may charge fees for the processing of cryptocurrency transactions which may not be reflected in the conversion prices displayed. Coinbase is not liable for any errors or delays in content, or for any actions taken in reliance on any content.


